ZYMEWORKS INC. Comprehensive Income
ZYMEWORKS INC. (ZYME) reported Comprehensive Income of -$45.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- ZYMEWORKS INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$45.15M, a 1994.59% decline year-over-year.
- ZYMEWORKS INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$44.65M.
- ZYMEWORKS INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$41.24M.
- ZYMEWORKS INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$19.31M.
- ZYMEWORKS INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$80.26M.
- ZYMEWORKS INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$123.04M.
- ZYMEWORKS INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$118.62M, a 195.40% decline from fiscal 2022.
- ZYMEWORKS INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was $124.34M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$45.15M 10-Q · filed 2026-08-06 | -$89.80M 10-Q · filed 2026-08-06 | -$131.03M derived: sum of 3 quarters · filed 2026-08-06 | -$150.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$44.65M 10-Q · filed 2026-05-07 | -$85.89M derived: sum of 2 quarters · filed 2026-05-07 | -$105.20M derived: sum of 3 quarters · filed 2026-05-07 | -$102.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$41.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$60.55M derived: sum of 2 quarters · filed 2026-03-02 | -$58.17M derived: sum of 3 quarters · filed 2026-08-06 | -$80.26M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$19.31M 10-Q · filed 2025-11-06 | -$16.93M derived: sum of 2 quarters · filed 2026-08-06 | -$39.02M 10-Q · filed 2025-11-06 | -$63.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.38M 10-Q · filed 2026-08-06 | -$19.71M 10-Q · filed 2026-08-06 | -$44.17M derived: sum of 3 quarters · filed 2026-08-06 | -$72.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$22.09M 10-Q · filed 2026-05-07 | -$46.55M derived: sum of 2 quarters · filed 2026-05-07 | -$74.49M derived: sum of 3 quarters · filed 2026-05-07 | -$112.36M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$24.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$52.40M derived: sum of 2 quarters · filed 2026-03-02 | -$90.27M derived: sum of 3 quarters · filed 2026-03-02 | -$123.04M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$27.95M 10-Q · filed 2025-11-06 | -$65.81M derived: sum of 2 quarters · filed 2025-11-06 | -$98.58M 10-Q · filed 2025-11-06 | -$111.37M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$37.87M 10-Q · filed 2025-08-07 | -$70.64M 10-Q · filed 2025-08-07 | -$83.43M derived: sum of 3 quarters · filed 2026-03-02 | -$112.60M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$32.77M 10-Q · filed 2025-05-08 | -$45.56M derived: sum of 2 quarters · filed 2026-03-02 | -$74.73M derived: sum of 3 quarters · filed 2026-03-02 | -$127.76M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$12.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$41.96M derived: sum of 2 quarters · filed 2026-03-02 | -$94.98M derived: sum of 3 quarters · filed 2026-03-02 | -$118.62M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$29.17M 10-Q · filed 2024-10-31 | -$82.20M derived: sum of 2 quarters · filed 2024-10-31 | -$105.83M 10-Q · filed 2024-10-31 | $203.60M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | -$53.03M 10-Q · filed 2024-08-01 | -$76.66M 10-Q · filed 2024-08-01 | $232.77M derived: sum of 3 quarters · filed 2025-03-05 | $184.93M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | -$23.63M 10-Q · filed 2024-05-02 | $285.80M derived: sum of 2 quarters · filed 2025-03-05 | $237.95M derived: sum of 3 quarters · filed 2025-03-05 | $173.33M derived: sum of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | $309.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $261.58M derived: sum of 2 quarters · filed 2025-03-05 | $196.97M derived: sum of 3 quarters · filed 2025-03-05 | $124.34M 10-K · filed 2025-03-05 |
| 2022-09-30 | -$47.85M 10-Q · filed 2023-11-07 | -$112.47M derived: sum of 2 quarters · filed 2023-11-07 | -$185.09M 10-Q · filed 2023-11-07 | -$224.24M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | -$64.62M 10-Q · filed 2023-08-10 | -$137.24M 10-Q · filed 2023-08-10 | -$176.40M derived: sum of 3 quarters · filed 2024-03-06 | -$236.97M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | -$72.63M 10-Q · filed 2023-05-08 | -$111.78M derived: sum of 2 quarters · filed 2024-03-06 | -$172.36M derived: sum of 3 quarters · filed 2024-03-06 | |
| 2021-12-31 | -$39.15M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$99.73M derived: sum of 2 quarters · filed 2024-03-06 | -$211.84M 10-K · filed 2024-03-06 | |
| 2021-09-30 | -$60.58M 10-Q · filed 2022-11-08 | -$172.69M 10-Q · filed 2022-11-08 | ||
| 2020-12-31 | -$180.55M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |